Summary
Global Markets Direct’s, ‘Bronchiectasis - Pipeline Review, H1 2016’, provides an overview of the Bronchiectasis pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Bronchiectasis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Bronchiectasis and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Bronchiectasis
- The report reviews pipeline therapeutics for Bronchiectasis by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Bronchiectasis therapeutics and enlists all their major and minor projects
- The report assesses Bronchiectasis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Bronchiectasis
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Bronchiectasis
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Bronchiectasis pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
Alitair Pharmaceuticals, Inc.
Bayer AG
Grifols, S.A.
Insmed Incorporated
Kamada Ltd.
Nostrum Pharmaceuticals, LLC
Polyphor Ltd.
Raptor Pharmaceutical Corp.
Recipharm AB
Savara Inc.
Therabron Therapeutics, Inc.
Vertex Pharmaceuticals Incorporated
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Bronchiectasis Overview 7
Therapeutics Development 8
Pipeline Products for Bronchiectasis - Overview 8
Bronchiectasis - Therapeutics under Development by Companies 9
Bronchiectasis - Pipeline Products Glance 10
Late Stage Products 10
Clinical Stage Products 11
Early Stage Products 12
Bronchiectasis - Products under Development by Companies 13
Bronchiectasis - Companies Involved in Therapeutics Development 14
Alitair Pharmaceuticals, Inc. 14
Bayer AG 15
Grifols, S.A. 16
Insmed Incorporated 17
Kamada Ltd. 18
Nostrum Pharmaceuticals, LLC 19
Polyphor Ltd. 20
Raptor Pharmaceutical Corp. 21
Recipharm AB 22
Savara Inc. 23
Therabron Therapeutics, Inc. 24
Vertex Pharmaceuticals Incorporated 25
Bronchiectasis - Therapeutics Assessment 26
Assessment by Monotherapy Products 26
Assessment by Target 27
Assessment by Mechanism of Action 29
Assessment by Route of Administration 31
Assessment by Molecule Type 33
Drug Profiles 35
alpha-1 proteinase inhibitor (human) second generation - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
amikacin sulfate - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
ARD-3150 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
CG-1011 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
ciprofloxacin hydrochloride - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
dapsone - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
doxofylline - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
erdosteine - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Leukotriene-B4 - Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
levofloxacin - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
PB-01 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
POL-7080 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
vancomycin hydrochloride - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
VX-371 - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
Bronchiectasis - Recent Pipeline Updates 63
Bronchiectasis - Dormant Projects 78
Bronchiectasis - Discontinued Products 79
Bronchiectasis - Product Development Milestones 80
Featured News & Press Releases 80
Mar 17, 2016: Aradigm Announces Decision for Centralized Review of Pulmaquin by the European Medicines Agency 80
Mar 16, 2016: Raptor Announces Qualified Infectious Disease Product Designation for MP-376, Inhaled Levofloxacin 80
Oct 13, 2015: Aradigm Completes Enrollment in the Second Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis 81
Sep 22, 2015: Aradigm Completes Enrollment in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 82
Jan 14, 2015: Aradigm Granted Key Composition of Matter Patents for Pulmaquin in Europe and Australia 82
Nov 24, 2014: FDA Grants QIDP Designation to Bayer's Ciprofloxacin Dry Powder for Inhalation 83
Sep 04, 2014: FDA Grants Fast Track Designation to Aradigm’s Pulmaquin for Non-Cystic Fibrosis Bronchiectasis 83
Jun 23, 2014: Aradigm Corporation Announces the Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis (ORBIT-4) 84
Jun 03, 2014: Aradigm Receives $5 Million Milestone For Dosing of the First Patient in Phase III Study of Pulmaquin in Non-Cystic Fibrosis Bronchiectasis 85
May 20, 2014: FDA Grants QIDP Designation to Aradigm’s Inhaled Antibiotic 85
Appendix 87
Methodology 87
Coverage 87
Secondary Research 87
Primary Research 87
Expert Panel Validation 87
Contact Us 87
Disclaimer 88
List of Tables
Number of Products under Development for Bronchiectasis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Comparative Analysis by Early Stage Development, H1 2016 12
Products under Development by Companies, H1 2016 13
Bronchiectasis - Pipeline by Alitair Pharmaceuticals, Inc., H1 2016 14
Bronchiectasis - Pipeline by Bayer AG, H1 2016 15
Bronchiectasis - Pipeline by Grifols, S.A., H1 2016 16
Bronchiectasis - Pipeline by Insmed Incorporated, H1 2016 17
Bronchiectasis - Pipeline by Kamada Ltd., H1 2016 18
Bronchiectasis - Pipeline by Nostrum Pharmaceuticals, LLC, H1 2016 19
Bronchiectasis - Pipeline by Polyphor Ltd., H1 2016 20
Bronchiectasis - Pipeline by Raptor Pharmaceutical Corp., H1 2016 21
Bronchiectasis - Pipeline by Recipharm AB, H1 2016 22
Bronchiectasis - Pipeline by Savara Inc., H1 2016 23
Bronchiectasis - Pipeline by Therabron Therapeutics, Inc., H1 2016 24
Bronchiectasis - Pipeline by Vertex Pharmaceuticals Incorporated, H1 2016 25
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Stage and Target, H1 2016 28
Number of Products by Stage and Mechanism of Action, H1 2016 30
Number of Products by Stage and Route of Administration, H1 2016 32
Number of Products by Stage and Molecule Type, H1 2016 34
Bronchiectasis Therapeutics - Recent Pipeline Updates, H1 2016 63
Bronchiectasis - Dormant Projects, H1 2016 78
Bronchiectasis - Discontinued Products, H1 2016 79
List of Figures
Number of Products under Development for Bronchiectasis, H1 2016 8
Number of Products under Development by Companies, H1 2016 9
Comparative Analysis by Late Stage Development, H1 2016 10
Comparative Analysis by Clinical Stage Development, H1 2016 11
Assessment by Monotherapy Products, H1 2016 26
Number of Products by Top 10 Targets, H1 2016 27
Number of Products by Stage and Top 10 Targets, H1 2016 27
Number of Products by Top 10 Mechanism of Actions, H1 2016 29
Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 29
Number of Products by Routes of Administration, H1 2016 31
Number of Products by Stage and Routes of Administration, H1 2016 31
Number of Products by Molecule Types, H1 2016 33
Number of Products by Stage and Molecule Types, H1 2016 33
